Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80.
Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T; BCN 01 study group. Mothe B, et al. Among authors: manzardo c. EClinicalMedicine. 2020 Jan 10;18:100250. doi: 10.1016/j.eclinm.2019.100250. eCollection 2020 Jan. EClinicalMedicine. 2020. PMID: 31956858 Free PMC article.
Renal dysfunction in the setting of HIV/AIDS.
Miro JM, Cofan F, Trullas JC, Manzardo C, Cervera C, Tuset M, Oppenheimer F, Brunet M, Moreno A, Campistol JM, Gatell JM. Miro JM, et al. Among authors: manzardo c. Curr HIV/AIDS Rep. 2012 Sep;9(3):187-99. doi: 10.1007/s11904-012-0125-9. Curr HIV/AIDS Rep. 2012. PMID: 22706955 Review.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group. Puertas MC, et al. Among authors: manzardo c. AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST Investigators. Kawana-Tachikawa A, et al. Among authors: manzardo c. PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014. PLoS One. 2014. PMID: 24475275 Free PMC article. Clinical Trial.
Update on antiretroviral treatment during primary HIV infection.
Ambrosioni J, Nicolas D, Sued O, Agüero F, Manzardo C, Miro JM. Ambrosioni J, et al. Among authors: manzardo c. Expert Rev Anti Infect Ther. 2014 Jul;12(7):793-807. doi: 10.1586/14787210.2014.913981. Epub 2014 May 7. Expert Rev Anti Infect Ther. 2014. PMID: 24803105 Review.
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group. Miro JM, et al. Among authors: manzardo c. J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567. J Acquir Immune Defic Syndr. 2015. PMID: 25831464 Clinical Trial.
127 results